Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;30(2):94-9.
doi: 10.4103/0970-9371.112650.

The Bethesda System for Reporting Thyroid Fine Needle Aspirates: A Cytologic Study With Histologic Follow-Up

Affiliations
Free PMC article

The Bethesda System for Reporting Thyroid Fine Needle Aspirates: A Cytologic Study With Histologic Follow-Up

Santosh Kumar Mondal et al. J Cytol. .
Free PMC article

Abstract

Background: The Bethesda system for reporting thyroid cytopathology represents a major step towards standardization, reproducibility, improved clinical significance, and greater predictive value of thyroid fine needle aspirates (FNAs).

Aims: To elucidate the utility of the Bethesda system in reporting thyroid FNAs.

Materials and methods: We retrospectively reviewed thyroid FNAs between April 2009 and March 2012, classified them using the Bethesda system, found out the distribution of cases in each Bethesda category, and calculated the malignancy risk for each category by follow-up histopathology.

Results: Of the 1020 FNAs, 1.2% were non-diagnostic, 87.5% were benign, 1% were atypical follicular lesion of undetermined significance (AFLUS), 4.2% were suspicious for follicular neoplasm (SFN), 1.4% were suspicious for malignancy (SM), and 4.7% malignant. Of 69 cases originally interpreted as non-diagnostic, 12 remained non-diagnostic after re-aspiration. In 323 cases, data of follow-up histopathologic examination (HPE) were available. Rates of malignancy reported on follow-up HPE were non-diagnostic 0%, benign 4.5%, AFLUS 20%, SFN 30.6%, SM 75%, and malignant 97.8%.

Conclusions: Reviewing the thyroid FNAs with the Bethesda system allowed a more specific cytological diagnosis. In this study, the distribution of cases in the Bethesda categories differed from some studies, with the number of benign cases being higher and the number of non-diagnostic and AFLUS cases being lower. The malignancy risk for each category correlated well with other studies. The Bethesda system thus allows standardization in reporting, improves perceptions of diagnostic terminology between cytopathologists and clinicians, and leads to more consistent management approaches.

Keywords: Bethesda system; fine needle aspiration; standardization; thyroid.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
(a) Microphotograph showing Hashimoto's thyroiditis with thyroid follicular cells showing Hurthle cell change and lymphocytes in the background, categorized into the benign category (Pap, ×400), (b) Microphotograph of a smear categorized as AFLUS, showing predominantly benign thyroid follicular cells in sheets, with some cells showing anisonucleosis and forming microfollicles (Pap, ×400)
Figure 2
Figure 2
Microphotograph of a smear categorized as papillary carcinoma. (a) Thyroid follicular cells arranged in papillae with anatomical borders (Pap, ×400), (b) Nuclear grooving and pseudoinclusion (arrow) (Pap ×400), (c) Cyst macrophages in the background (LG, ×400), (d) Multinucleated giant cells (LG ×400)

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles

References

    1. Cibas ES. Fine-needle aspiration in the work-up of thyroid nodules. Otolaryngol Clin North Am. 2010;43:257–71. - PubMed
    1. Redman R, Yoder BJ, Massoll NA. Perceptions of diagnostic terminology and cytopathologic reporting of fine-needle aspiration biopsies of thyroid nodules: A survey of clinicians and pathologists. Thyroid. 2006;16:1003–8. - PubMed
    1. Lewis CM, Chang KP, Pitman M, Faquin WC, Randolph GW. Thyroid fine-needle aspiration biopsy: Variability in reporting. Thyroid. 2009;19:717–23. - PubMed
    1. Guidelines of the Papanicolaou Society of Cytopathology for fine-needle aspiration procedure and reporting. The Papanicolaou society of cytopathology task force on standards of practice. Diagn Cytopathol. 1997;17:239–47. - PubMed
    1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42. - PubMed
Feedback